File(s) not publicly available

Seven risks emerging from life patents and corporate science

journal contribution
posted on 06.12.2017, 00:00 by Merryn EkbergMerryn Ekberg
This article examines some of the controversial issues emerging from the privatization of biomedical research and commercialization of biotechnology. The aim is to identify the dominant social, political, and ethical risks associated with the recent shift from academic to corporate science and from the increasing emphasis on investing in research projects that will result in the award of a monopoly patent. Identifying these risks may ultimately assist policy makers in designing new policies or reforming existing practices that will come closer to achieving an equitable balance between science pursued for the advance of knowledge and science pursued for patents and profit. The discussion may also assist the research directors or managers of biopharmaceutical companies in designing corporate policies that will optimize the balance between the serendipity of scientific discovery and the discipline of strategic business planning.

Funding

Category 1 - Australian Competitive Grants (this includes ARC, NHMRC)

History

Volume

25

Issue

6

Start Page

475

End Page

483

Number of Pages

9

ISSN

1552-4183

Location

USA

Publisher

Sage Publications

Language

en-aus

Peer Reviewed

Yes

Open Access

No

External Author Affiliations

Faculty of Arts, Health and Sciences; TBA Research Institute;

Era Eligible

Yes

Journal

Bulletin of science, technology and society.